What is HPTN 083?

An HIV prevention study evaluating the efficacy of the long-acting injectable agent, Cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected men and transgender women who have sex with men. PrEP agents are needed that do not depend on daily or near-daily pill-taking. Long-acting injectable agents have the potential to prevent HIV acquisition without relying on adherence to a daily oral regimen. This study will enroll approximately 4500 HIV-uninfected men and transgender women who have sex with men at risk for acquiring HIV infection in the Americas, Asia and South Africa. Participants will be compensated for their time and travel.

To join participants must be:

v A man who has sex with other men

v A transgender woman who has sex with men

v 18 – 50 years of age

v HIV negative

Compensation provided for all visits!

 

 


What is AMP?

AMP stands for Antibody Mediated Prevention. This is the idea of giving people antibodies that fight HIV to see if they will protect people from becoming HIV infected. Antibodies are one of the natural ways the body fights infection. The AMP study is testing an antibody called VRC01, a manufactured antibody against HIV designed to protect people from becoming HIV infected. This is a new idea for HIV prevention. You CANNOT get HIV from participating in this study. The study will enroll 2,700 HIV-uninfected men and transgender people who have sex with men in North America, South America, and Switzerland. Participants will be compensated for their time and travel.

To join participants must be:

v A man who has sex with other men

v A transgender individual who has sex with men

v 18 – 50 years of age

v HIV negative

Compensation provided for all visits!

 

For more info about HPTN 083 and AMP please contact 866-449-UCLA or email [email protected]